Did you forget your password? Please enter your e-mail address below and click Submit. Your password will be e-mailed to you shortly.
- Oncologic Drugs AdComm
Meeting Date: 7/9/15-7/9/15
The committee will discuss biologics license application 125547, necitumumab injection, application submitted by Eli Lilly and Company. The proposed indication (use) for this product is in combination with gemcitabine and cisplatin for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer.
|Location:||FDA Meeting Room||Related News Links:||Not Available|